Is Everest Organics overvalued or undervalued?

As of 14 November 2025, Everest Organics has moved from an expensive valuation grade to fair. The company is currently fairly valued, with a PE ratio of 62.63, an EV to EBITDA ratio of 27.20, and a PEG ratio of 0.31. In comparison to its peers, Sun Pharma has a PE ratio of 36.49 and an EV to EBITDA of 24.09, while Divi's Lab is significantly more expensive with a PE ratio of 69.65 and an EV to EBITDA of 52.35.
Despite its high valuation ratios, Everest Organics shows a relatively attractive PEG ratio, indicating potential for growth compared to its price. The company's recent stock performance has outpaced the Sensex, with a year-to-date return of 41.84% compared to the Sensex's 8.22%, reinforcing the notion that it is fairly valued given its growth prospects in the pharmaceuticals and biotechnology sector.